S&P removes drugmaker Wyeth from 2 indices in sign $68B acquisition by Pfizer will go throughOctober 2nd, 2009 S&P removes Wyeth from indices before acquisitionTRENTON, N.J. — In the latest sign that Pfizer Inc.'s $68 billion purchase of Wyeth will go through, Wyeth's stock has been removed from two key investor indices.
Drugmaker Merck seeks EU approval for $41B acquisition of Schering-Plough, expects ruling soonSeptember 21st, 2009 Merck seeks EU approval to buy Schering-PloughTRENTON, N.J. — Drugmaker Merck & Co.
Elan sees Johnson & Johnson cut partnership deal value on amendment after contract breachSeptember 14th, 2009 Elan sees J&J cut deal value in contract amendmentNEW YORK — Elan Corp. said Monday Johnson & Johnson will reduce the value of a partnership deal under an amendment as part of a move meant to fix a contract breach with Biogen Idec Inc.
Elan says federal judge ruled it broke terms of Tysabri deal with Biogen IdecSeptember 4th, 2009 Elan says court rules against it in Biogen caseNEW YORK — Irish drugmaker Elan says a federal judge ruled it violated the terms of an agreement with Biogen Idec to market the multiple sclerosis treatment Tysabri when it struck a separate deal to collaborate with Johnson & Johnson. Elan Corp. PLC said in a statement late Thursday that it respects the court decision and plans to complete its deal with Johnson & Johnson while staying in compliance with its earlier deal with Biogen Idec Inc.
Shareholders of Merck, Schering-Plough to vote on combination, would create No. 2 drugmakerAugust 7th, 2009 Merck takeover of Schering-Plough up for voteTRENTON, N.J. — Shareholders will decide Friday whether two New Jersey drug companies will become the world's second-biggest drugmaker.
Schering-Plough shareholders back $41.1 billion acquisition by partner Merck & Co.August 7th, 2009 Schering-Plough shareholders OK purchase by MerckTRENTON, N.J. — Shareholders of drugmaker Schering-Plough almost unanimously support being bought by bigger New Jersey neighbor Merck.
Elan's losses narrow as sales of MS-fighting drug Tysabri growJuly 21st, 2009 Elan's 2Q loss narrows as MS drug sales growDUBLIN — Losses are narrowing at Elan Corp. PLC as sales of its key drug, the multiple sclerosis-fighting Tysabri, keep growing in the United States and Europe, the Irish biopharmaceutical company reported Tuesday.
Nebraska regulators order Omaha investment manager to quit violating law with improper feesJuly 6th, 2009 State regulators target Omaha investment adviserOMAHA, Neb. — Nebraska regulators have ordered an Omaha investment adviser to quit violating state securities laws and appear at a hearing to defend his practices.
House subpoenas documents that could shed new light on Fed's role in Bank of America mergerJune 19th, 2009 House targets Fed in Bank of America investigationWASHINGTON — A House panel has subpoenaed documents that lawmakers say could shed new light on Federal Reserve Chairman Ben Bernanke's role in Bank of America's acquisition of Merrill Lynch. The subpoena comes ahead of a hearing next week in which Bernanke is scheduled to testify.
Farmed fish may transmit mad cow diseaseJune 17th, 2009 WASHINGTON - Farmed fish, if fed by-products rendered from cows, could transmit Creutzfeldt Jakob disease-commonly known as mad cow disease. Questioning the safety of eating farmed fish, Dr.
Biogen Idec says activist Carl Icahn wins board seat for candidate; 2nd seat too close to callJune 4th, 2009 Biogen Idec says Icahn candidate wins board seatCAMBRIDGE, Mass. — Biogen Idec Inc.
Biogen Idec calls recess at annual meeting as proxy fight with Carl Icahn heats upJune 3rd, 2009 Biogen calls proxy vote recess in fight with IcahnNEW YORK — Biogen Idec Inc. called a recess at its annual meeting Wednesday as activist investor Carl Icahn attempted to place dissident nominees on the board amid a contentious yearslong fight with the company.
Correction: Drugmaker dollars storyMay 1st, 2009 Correction: Drugmaker dollars storyWASHINGTON — In several versions of an April 28 story about a report on the influence of drugmaker money in medicine, The Associated Press reported erroneously that the head of Stanford University's psychiatry department had stepped down under criticism by a U.S. senator over payments made to him by drugmakers.
Calif. regulators seize lead-tainted religious, children's jewelry, most imported from ChinaApril 28th, 2009 Calif. finds lead-tainted religious, kids' jewelryLOS ANGELES — California regulators say they've found religious and children's jewelry with dangerously high lead levels at stores and warehouses. The state Department of Toxic Substances Control says material taken from one children's necklace was 74 percent lead.
Michael J. Fox refuses to let Parkinson's disease define himMarch 31st, 2009 WASHINGTON - 'Back to the Future' star Michael J. Fox has revealed that he refuses to let his battle with Parkinson's disease stop him from living his life or from defining him.
Loading ...